Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 12
1983 3
1984 2
1985 4
1986 9
1987 13
1988 7
1989 18
1990 23
1991 18
1992 15
1993 11
1994 18
1995 10
1996 16
1997 18
1998 14
1999 10
2000 10
2001 14
2002 7
2003 17
2004 4
2005 8
2006 9
2007 9
2008 6
2009 11
2010 8
2011 5
2012 14
2013 8
2014 8
2015 8
2016 5
2017 6
2018 3
2019 2
2020 6
2021 2
2022 3
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Results by year

Filters applied: . Clear all
Page 1
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group. Rush AJ, et al. Control Clin Trials. 2004 Feb;25(1):119-42. doi: 10.1016/s0197-2456(03)00112-0. Control Clin Trials. 2004. PMID: 15061154 Clinical Trial.
After receiving citalopram (level 1), participants without sufficient symptomatic benefit are eligible for randomization to level 2 treatments, which entail four switch options (sertraline, bupropion, venlafaxine, cognitive therapy) and three citalopram augment options (bupropion …
After receiving citalopram (level 1), participants without sufficient symptomatic benefit are eligible for randomization to level 2 treatmen …
Minimal handgrip force is needed for transcutaneous electrical stimulation to improve hand functions of patients with severe spinal cord injury.
Huang R, Nikooyan AA, Moore LD, Zdunowski S, Morikawa E, Sierro T, Sayenko D, Gad P, Homsey T, Le T, Madhavan MA, Abdelshahid M, Abdelshahid M, Zhou Y, Nuwer MR, Sarrafzadeh M, Edgerton VR, Leiter JC, Lu DC. Huang R, et al. Sci Rep. 2022 May 11;12(1):7733. doi: 10.1038/s41598-022-11306-5. Sci Rep. 2022. PMID: 35545644 Free PMC article. Clinical Trial.
All treatments-busp, tSCS, and the busp plus tSCS-reduced muscle tone and spasm frequency. Buspirone did not have any discernible impact on grip force or manual dexterity when administered alone or in combination with tSCS. ...Buspirone did not significantly improve …
All treatments-busp, tSCS, and the busp plus tSCS-reduced muscle tone and spasm frequency. Buspirone did not have any discernible imp …
Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P. Zhou X, et al. J Clin Psychiatry. 2015 Apr;76(4):e487-98. doi: 10.4088/JCP.14r09204. J Clin Psychiatry. 2015. PMID: 25919841 Clinical Trial.
STUDY SELECTION: Randomized controlled trials comparing 11 augmentation agents (aripiprazole, bupropion, buspirone, lamotrigine, lithium, methylphenidate, olanzapine, pindolol, quetiapine, risperidone, and thyroid hormone) with each other and with placebo for adult treatme …
STUDY SELECTION: Randomized controlled trials comparing 11 augmentation agents (aripiprazole, bupropion, buspirone, lamotrigine, lith …
Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain: A Randomized Clinical Trial.
Badihian N, Yaghini O, Badihian S, Shahsanai A, Saneian H. Badihian N, et al. Am J Gastroenterol. 2020 May;115(5):756-765. doi: 10.14309/ajg.0000000000000589. Am J Gastroenterol. 2020. PMID: 32221160 Clinical Trial.
We randomly assigned patients to receive buspirone or placebo for 4 weeks, with the adjusted dosage for age. ...Further studies, with the higher doses of buspirone and longer follow-ups are recommended....
We randomly assigned patients to receive buspirone or placebo for 4 weeks, with the adjusted dosage for age. ...Further studies, with …
Buspirone: anxiolytic?
Pecknold JC, Familamiri P, Chang H, Wilson R, Alarcia J, McClure DJ. Pecknold JC, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):639-42. doi: 10.1016/0278-5846(85)90032-6. Prog Neuropsychopharmacol Biol Psychiatry. 1985. PMID: 2868495 Clinical Trial.
The HAM-A score was significantly lower in the diazepam group at week 2 (p less than .02) and the buspirone group at week 3 (p less than .04) as compared to the placebo group. ...Withdrawal symptoms were more evident in the diazepam group than the buspirone group... …
The HAM-A score was significantly lower in the diazepam group at week 2 (p less than .02) and the buspirone group at week 3 (p less t …
Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial.
Giannoni A, Borrelli C, Mirizzi G, Richerson GB, Emdin M, Passino C. Giannoni A, et al. Eur J Heart Fail. 2021 Feb;23(2):312-320. doi: 10.1002/ejhf.1854. Epub 2020 May 22. Eur J Heart Fail. 2021. PMID: 32441857 Free article. Clinical Trial.
In the intention-to-treat analysis, more patients treated with buspirone (8/16, 50%) had a CO(2) chemosensitivity reduction >0.5 L/min/mmHg from baseline than those treated with placebo (1/16, 6.7%) (difference between groups 43%, 95% confidence interval 14-73%, P = 0.0 …
In the intention-to-treat analysis, more patients treated with buspirone (8/16, 50%) had a CO(2) chemosensitivity reduction >0.5 L …
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
Schneider RB, Auinger P, Tarolli CG, Iourinets J, Gil-Díaz MC, Richard IH. Schneider RB, et al. Parkinsonism Relat Disord. 2020 Dec;81:69-74. doi: 10.1016/j.parkreldis.2020.10.020. Epub 2020 Oct 13. Parkinsonism Relat Disord. 2020. PMID: 33070009 Free PMC article. Clinical Trial.
In the buspirone group, 7 (41%) failed to complete the study on drug, 5 due to intolerability. The median buspirone dosage was 7.5 mg twice daily. No serious adverse events occurred. ...
In the buspirone group, 7 (41%) failed to complete the study on drug, 5 due to intolerability. The median buspirone dosage was …
A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder.
Ross CA, Matas M. Ross CA, et al. Can J Psychiatry. 1987 Jun;32(5):351-5. doi: 10.1177/070674378703200505. Can J Psychiatry. 1987. PMID: 3308052 Clinical Trial.
In double-blind trials with hundreds of patients, buspirone has proven to be as effective an anxiolytic as the benzodiazepines. ...Maximum doses were 40 mg of diazepam or buspirone or eight placebo tablets a day. There were no significant differences in outcome betw …
In double-blind trials with hundreds of patients, buspirone has proven to be as effective an anxiolytic as the benzodiazepines. ...Ma …
A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.
Bergeria CL, Tan H, Antoine D, Weerts EM, Huhn AS, Hobelmann JG, Dunn KE. Bergeria CL, et al. Exp Clin Psychopharmacol. 2023 Feb;31(1):194-203. doi: 10.1037/pha0000550. Epub 2022 Mar 10. Exp Clin Psychopharmacol. 2023. PMID: 35266779 Clinical Trial.
Total SOWS scores significantly decreased across study phases for both groups but decreased to a greater extent among individuals assigned to buspirone during both the first and second week of stable buspirone. ...Buspirone may confer unique benefits during p …
Total SOWS scores significantly decreased across study phases for both groups but decreased to a greater extent among individuals assigned t …
A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism.
Ghanizadeh A, Ayoobzadehshirazi A. Ghanizadeh A, et al. Pediatr Neurol. 2015 Jan;52(1):77-81. doi: 10.1016/j.pediatrneurol.2014.09.017. Epub 2014 Oct 5. Pediatr Neurol. 2015. PMID: 25451017 Clinical Trial.
RESULTS: Eighteen patients in the placebo group and 16 patients in the buspirone group completed this trial. The mean dose of buspirone was 6.7 (SD 2.7) mg/day. ...There were no serious adverse effects. The most common adverse effects in the buspirone group w …
RESULTS: Eighteen patients in the placebo group and 16 patients in the buspirone group completed this trial. The mean dose of busp …
378 results